Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.74 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 7/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17679355 | 1.00 | PDPK1 (0.74) | PDPK1NTRK1BRD4HTTPTPRC | |
| SCHEMBL17674469 | 1.00 | PDPK1 (0.74) | PDPK1NTRK1BRD4HTTPTPRC | |
| SCHEMBL24966373 | 0.91 | PDPK1 (0.75) | PDPK1NTRK1BRD4PAK4JAK3 | |
| SCHEMBL24966364 | 0.90 | PDPK1 (0.71) | PDPK1NTRK1BRD4KMT2AMEN1 | |
| SCHEMBL30155011 | 0.90 | PDPK1 (0.71) | PDPK1NTRK1BRD4KMT2AMEN1 | |
| SCHEMBL30155056 | 0.87 | PDPK1 (0.67) | PDPK1NTRK1BRD4HTTPAK4 | |
| SCHEMBL23369102 | 0.85 | PDPK1 (1.00) | PDPK1NTRK1BRD4MAP4K1PAK4 | |
| SCHEMBL17674461 | 0.85 | PDPK1 (1.00) | PDPK1NTRK1BRD4MAP4K1PAK4 | |
| SCHEMBL17679291 | 0.85 | PDPK1 (1.00) | PDPK1NTRK1BRD4MAP4K1PAK4 | |
| SCHEMBL5358922 | 0.82 | PDPK1 (0.63) | PDPK1NTRK1BRD4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350458-A1 | 14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS | RAPPOSELLI SIMONA (IT) | 2024-10-24 | — | — | US | disclosed |
| WO-2024153596-A1 | 14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS | GAUDIO EUGENIO (CH) | 2024-07-25 | — | — | WO | disclosed |
| EP-4373488-A1 | 14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS | Rapposelli, Simona (IT) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023001942-A1 | 14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS | RAPPOSELLI SIMONA (IT) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001942-A1 | 14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS | RAPPOSELLI SIMONA (IT) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350458-A1 | 14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS | YWHAH, YWHAB, YWHAG | PDPK1 3587/4885NTRK1 460/4885BRD4 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.